Revolutionizing Treatment Options with SELARSDI
Teva Pharmaceuticals and Alvotech are excited to announce that SELARSDI™ (ustekinumab-aekn) injection has received approval to be available to patients across the United States. This strategic partnership between the two companies has resulted in the launch of their second biosimilar product in the U.S. market, following their collaborative efforts that have led to the development of innovative treatments that promise cost-effective healthcare solutions.
The Significance of SELARSDI
FDA Approval and Interchangeability
In a groundbreaking achievement, the U.S. Food and Drug Administration (FDA) has approved SELARSDI for all indications that align with Stelara (ustekinumab), which is the reference product. This approval means that SELARSDI will also be recognized as interchangeable with Stelara after the exclusivity period expires on April 30, 2025. The introduction of SELARSDI not only meets the growing demand for effective treatments but also demonstrates the commitment of Teva and Alvotech to enhance patient care.
Conditions Treated with SELARSDI
SELARSDI has been approved for multiple serious medical conditions, including moderate to severe plaque psoriasis and active psoriatic arthritis. It is also indicated for adults with moderately to severely active Crohn’s disease and ulcerative colitis, as well as for pediatric patients aged six and older suffering from the same conditions. This diverse range of applications underscores the significant role that SELARSDI will play in the healthcare sector.
Your Health Matters: Understanding the Benefits
Cost Savings Across Healthcare
Healthcare professionals are increasingly recognizing the potential cost savings that biosimilars like SELARSDI can provide within the healthcare system. According to Thomas Rainey, Senior Vice President of U.S. Biosimilars at Teva, the launch of SELARSDI offers patients and providers access to essential treatment options at more affordable prices, thereby removing barriers to essential care.
A Joint Commitment to Quality
Alvotech's Chief Commercial Officer, Anil Okay, emphasized that the launch of SELARSDI is a defining moment for their partnership and an affirmation of their dedication to delivering affordable treatment options. The collaboration focuses on developing a portfolio of high-quality biologics that can contribute significantly to reducing healthcare costs worldwide.
What Makes SELARSDI Unique?
Development and Production
SELARSDI is produced using a robust process that utilizes Sp2/0 cells with continuous perfusion technology, which matches the production process used for Stelara. This careful approach ensures that the biosimilar meets high standards of safety and efficacy, reinforcing the confidence that healthcare providers can have in SELARSDI as a treatment option.
Diverse Presentations Available
SELARSDI comes in several approved presentations, including prefilled syringes for subcutaneous injection and single-dose vials, allowing flexibility for both physicians and patients. This variety is crucial in addressing diverse patient needs and preferences.
About Teva and Alvotech
Teva Pharmaceutical Industries
Teva is recognized globally as a leading pharmaceutical company, with over 120 years of experience in developing essential medicines. Their commitment to innovation and quality has positioned them as a frontrunner in the pharmaceutical industry. Teva operates in more than 57 markets worldwide, underscoring their dedication to health and well-being.
Alvotech's Focus on Biosimilars
Alvotech specializes in biosimilar medicines, aiming to be a leader in this innovative field. Their commitment to high-quality, cost-effective products aligns perfectly with the needs of healthcare systems globally. The collaboration with Teva enhances their reach and impact in bringing life-saving treatments to the market.
Frequently Asked Questions
What is SELARSDI?
SELARSDI is a biosimilar injection developed by Teva and Alvotech, designed to treat various autoimmune diseases such as psoriasis and Crohn’s disease.
Which conditions can SELARSDI treat?
It is approved for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis in both adults and pediatric patients.
How does SELARSDI compare to Stelara?
SELARSDI is approved as an interchangeable biosimilar to Stelara, meaning it has similar efficacy and safety profiles while potentially offering cost benefits.
What are the potential side effects of SELARSDI?
Common side effects may include infections, allergic reactions, and gastrointestinal complications, among others. It is crucial to discuss potential risks with a healthcare provider.
Where can I find more information about SELARSDI?
For detailed information about SELARSDI, patients and healthcare professionals can refer to the prescribing information available through healthcare providers or official company communications.
